GSK senior VP-worldwide development
Executive Summary
AstraZeneca Senior VP-U.S. Drug Development Ronald Krall, MD, joins GlaxoSmithKline as senior VP-worldwide development, research & development, effective Feb. 19. Krall succeeds James Palmer, MD, who served as senior VP-new product development and left GSK in October to become Bristol Myers-Squibb chief scientific officer (1"The Pink Sheet" Oct. 28, 2002, p. 15). AstraZeneca VP-Clinical Development Glenn Gormley, MD, is succeeding Krall on an acting basis....
You may also be interested in...
Bristol Continues R&D Outsourcing: GSK VP Palmer Named CSO
Bristol-Myers Squibb Chief Scientific Officer-designate James Palmer, MD, brings 15 years of experience in clinical development at Glaxo and its successor companies
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.